|Mr. John Lai||CEO, Pres & Director||228.24k||N/A||1962|
|Mr. Robert J. Folkes||Chief Financial Officer||322.41k||N/A||1963|
|Mr. Randall A. Meyer||Chief Operating Officer||259.84k||N/A||1964|
|Mr. Randy Wenthold||Chief Science Officer||N/A||N/A||N/A|
|Mr. John F. Dolan||Gen. Counsel, Chief Bus. Devel. Officer & Sec.||N/A||N/A||1965|
|Mr. Gary DeMel||Exec. VP of Bus. Devel.||N/A||N/A||1957|
|Mr. Russell Siakel||Director of Marketing||N/A||N/A||N/A|
|Mr. Mark Middleton||National Director of Sales||N/A||N/A||N/A|
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
PetVivo Holdings, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.